Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.

Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ.

Ann Rheum Dis. 2014 May;73(5):871-82. doi: 10.1136/annrheumdis-2012-203116. Epub 2013 Apr 18. Review.

PMID:
23599436
2.

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.

Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, Checchio T, Tensfeldt TG, Hoffman E, Riese R, Boy M, Gómez-Reino JJ.

Arthritis Res Ther. 2015 Dec 15;17:362. doi: 10.1186/s13075-015-0880-2. Review.

3.

Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.

Vyas D, O'Dell KM, Bandy JL, Boyce EG.

Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790. Review.

PMID:
24285764
4.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

PMID:
16030080
5.

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Salliot C, Dougados M, Gossec L.

Ann Rheum Dis. 2009 Jan;68(1):25-32. doi: 10.1136/ard.2007.083188. Epub 2008 Jan 18. Review.

6.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
7.

Neuromodulators for pain management in rheumatoid arthritis.

Richards BL, Whittle SL, Buchbinder R.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008921. doi: 10.1002/14651858.CD008921.pub2. Review.

PMID:
22258992
8.

Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.

Barnabe C, Martin BJ, Ghali WA.

Arthritis Care Res (Hoboken). 2011 Apr;63(4):522-9. doi: 10.1002/acr.20371. Review.

9.

Abatacept for rheumatoid arthritis: a Cochrane systematic review.

Maxwell LJ, Singh JA.

J Rheumatol. 2010 Feb;37(2):234-45. doi: 10.3899/jrheum.091066. Epub 2010 Jan 15. Review. Erratum in: J Rheumatol. 2010 Mar;37(3):682.

PMID:
20080922
10.

Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.

Curtis JR, Zhang R, Krishnaswami S, Anisfeld A, Chen Y, Strengholt S, Chen C, Geier J.

Clin Rheumatol. 2017 Mar;36(3):683-688. doi: 10.1007/s10067-016-3359-x. Epub 2016 Jul 28.

11.

[Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].

Hernández-Cruz B, García-Arias M, Ariza Ariza R, Martín Mola E.

Reumatol Clin. 2011 Sep-Oct;7(5):314-22. doi: 10.1016/j.reuma.2011.03.004. Epub 2011 Aug 2. Review. Spanish.

12.

Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.

MacFarlane LA, Todd DJ.

Int J Rheum Dis. 2014 May;17(4):359-68. doi: 10.1111/1756-185X.12293. Epub 2014 Jan 27. Review.

PMID:
24460872
13.

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L.

Ann Rheum Dis. 2014 Mar;73(3):510-5. doi: 10.1136/annrheumdis-2013-204588. Epub 2014 Jan 6. Review.

14.

Herbal therapy for treating rheumatoid arthritis.

Cameron M, Gagnier JJ, Chrubasik S.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD002948. doi: 10.1002/14651858.CD002948.pub2. Review.

PMID:
21328257
15.
16.

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.

Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M; REAL Study Group.

J Rheumatol. 2011 Jul;38(7):1258-64. doi: 10.3899/jrheum.101009. Epub 2011 Apr 15.

PMID:
21498482
17.

Antidepressants for pain management in rheumatoid arthritis.

Richards BL, Whittle SL, Buchbinder R.

Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008920. doi: 10.1002/14651858.CD008920.pub2. Review.

PMID:
22071859
18.

[JAK inhibitor].

Yamaoka K, Tanaka Y.

Nihon Rinsho. 2013 Jul;71(7):1243-7. Review. Japanese.

PMID:
23961674
19.

Selective JAK inhibitors in development for rheumatoid arthritis.

Norman P.

Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12. Review.

PMID:
24818516
20.

Kinase inhibitors: a new class of antirheumatic drugs.

Kyttaris VC.

Drug Des Devel Ther. 2012;6:245-50. doi: 10.2147/DDDT.S25426. Epub 2012 Sep 21. Review.

Supplemental Content

Support Center